November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says
April 8th 2019Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Read More
Updates to NCCN Guidelines on Molecular Assays for Patients With Breast Cancer
April 8th 2019William J. Gradishar, MD, discusses the NCCN guidelines in regard to selecting molecular assays for patients with breast cancer. Currently, there are 3 available assays that clinicians can order: 21-gene, 50-gene, and 70-gene assays.
Watch
Despite Slow Adoption, Artificial Intelligence Pilot Programs Yield Practical Results
April 6th 2019Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
Read More
Palbociclib Approved by FDA for Treatment of Male Patients With HR+/HER2- Breast Cancer
April 5th 2019The indication for palbociclib capsules in combination with endocrine therapy now includes the treatment of male patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer after being expanded by the FDA.
Read More
Surgeons' Association Calls for Change in National Breast Cancer Guidelines
April 2nd 2019It is rare that treatment guidelines make sweeping changes to treatment recommendations, yet the American Society of Breast Surgeons is urging that the National Comprehensive Cancer Network guidelines on breast cancer treatment be changed to indicate that genetic testing be offered to all patients with breast cancer.
Read More
Encouraging pCR Rate Seen With T-VEC Plus Chemo in TNBC
April 1st 2019Five of 9 patients with large triple-negative breast tumors treated with the viral oncolytic talimogene laherparepvec plus neoadjuvant chemotherapy achieved pathologic complete response, according to findings from a preliminary trial.
Read More
FDA Proposes Updates to Mammography Standards for First Time in 20 Years
March 28th 2019In an effort to enable healthcare providers and patients to make more informed medical decisions, the FDA has proposed amendments to key policies to modernize breast cancer screening and improve mammography services.
Read More
Application Withdrawn for Eflapegrastim as Treatment for Chemotherapy-Induced Neutropenia
March 19th 2019The biologics license application for eflapegrastim was voluntarily withdrawn by Spectrum Pharmaceuticals as the company requires more time to complete additional manufacturing-related information requested by the FDA.
Read More
Novel Agents May Challenge Standard Therapy in Advanced HER2+ Breast Cancer
March 15th 2019The treatment paradigm for HER2-positive breast cancer may be reshaped over the next several years, as head-to-head studies comparing new agents to the current standard of care begin to yield results, said Sara A. Hurvitz, MD.
Read More
CMS Mulls Opposition to Downsizing Part D Protected Drug Classes
March 15th 2019The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.
Read More
Exploring the Emerging Role of Antibody-Drug Conjugates in TNBC
March 14th 2019The need for new therapies to treat metastatic triple-negative breast cancer is pressing, and the development of antibody-drug conjugates represents a promising new strategy for these patients, according to Aditya Bardia, MD, MPH.
Read More
Panel Addresses Integration of PARP Inhibitors Into Breast Cancer Space
March 13th 2019At the <em>36th Annual </em>Miami Breast Cancer Conference<sup>®</sup>, a panel of experts discussed the use of 2 FDA-approved PARP inhibitors for patients with HER2-negative advanced or metastatic breast cancer whose tumors are positive for germline <em>BRCA1/2 </em>mutations.
Read More
Avoiding Overtreatment Saves Medicare $320M Over 3-Year Period in Older Men With Prostate Cancer
March 13th 2019Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.
Read More
Fourth Trastuzumab Biosimilar Granted Approval by FDA
March 12th 2019A fourth trastuzumab biosimilar has been granted approval by the FDA. The approval was for PF-05280014 for the treatment of patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More
Atezolizumab/Nab-Paclitaxel Approved by the FDA for PD-L1+ TNBC
March 8th 2019An accelerated approval has been granted by the FDA for the combination of atezolizumab and nab-paclitaxel as a frontline treatment for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.
Read More
Stilwill Highlights Benefit of CDK4/6 Inhibitors Across HR+/HER2- Breast Cancer Settings
March 5th 2019Joseph F. Stilwill, MD, shares insight on the benefit seen with CDK4/6 inhibitors in patients with advanced HR-positive, HER2-negative breast cancer and highlighted ongoing research aimed at overcoming acquired resistance.
Read More
Reduced Palbociclib Dose Associated With Lower Rate of Neutropenia in HR+ Metastatic Breast Cancer
March 5th 2019Hope Rugo, MD, discusses results from a trial that evaluated a reduced dose of palbociclib in patients with HR+ metastatic breast cancer. She also shares details from research for a scalp cooling cap to reduce hair loss for patients with breast cancer.
Read More
Early Findings Show Activity With Neoadjuvant Pembrolizumab Regimen in TNBC
March 1st 2019According to preliminary findings from the phase Ib KEYNOTE-173 trial, combining the PD-1 inhibitor pembrolizumab with platinum/taxane chemotherapy led to high rates of pathologic complete response in patients with locally advanced triple-negative breast cancer.
Read More
Subcutaneous Trastuzumab Formulation Receives FDA Approval for HER2+ Breast Cancer
February 28th 2019Subcutaneous use of trastuzumab and hyaluronidase-oysk injection has been approved by the FDA in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, in combination with paclitaxel in patients with metastatic HER2-positive breast cancer as a frontline treatment, and alone for patients with metastatic disease who have received at least 1 prior chemotherapy regimen.
Read More
Expert Reviews CDK4/6 Inhibitor Data in HR+/HER2- Breast Cancer
February 21st 2019Neelima Denduluri, MD, discusses each CDK4/6 inhibitor as potential first-line and second-line therapies based on the data from the PALOMA-2, MONALEESA-2 and -7, and MONARCH 3 trials, which led to their approvals.
Read More
Margetuximab Demonstrates Positive PFS Findings in Metastatic HER2+ Breast Cancer
February 7th 2019Patients with heavily pretreated metastatic HER2-positive breast cancer saw an improvement in progression-free survival with margetuximab combined with chemotherapy compared with trastuzumab and chemotherapy, according to findings from the phase III SOPHIA trial.
Read More
Adjuvant T-DM1 Submitted for FDA Approval in High-Risk HER2+ Breast Cancer
February 5th 2019A supplemental Biologics License Application for ado-trastuzumab emtansine (T-DM1; Kadcyla) has been submitted to the FDA seeking approval for the agent as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy.
Read More